Premium
Strategies for the Inhibition of Protein Aggregation in Human Diseases
Author(s) -
Bartolini Manuela,
Andrisano Vincenza
Publication year - 2010
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.200900666
Subject(s) - protein aggregation , disease , protein folding , drug discovery , computational biology , amyloid fibril , neuroscience , drug , biology , bioinformatics , medicine , amyloid β , pharmacology , biochemistry , pathology
Protein misfolding and aggregation has been related to several human disorders, generally termed protein aggregation diseases. These diseases include neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases and peripheral disorders such as systemic amyloidosis and type 2 diabetes. The complexity of the aggregation processes and the intertwined events account for the fact that no effective disease‐modifying treatments for these disorders are currently available. Nevertheless, in‐depth research into the aggregation processes has recently yielded major insights into some key mechanisms of aggregation‐mediated cell toxicity, offering new targets for drug development. In addition, recent findings in the field have identified similar features, revealing the possibility of shared mechanisms and hence potential common approaches for intervention. This review aims to give an overview of potential strategies for tackling protein aggregation and its associated toxicity, focusing on protein aggregation in human disease.